Technical analysis of Skye Bioscience, Inc. (SKYE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc.
Price Performance
| 1 month | -40.77% |
| 3 months | -69.96% |
| Year-to-date | -71.67% |
| 1 year | -94.57% |
| 3 years | -90.07% |
| 5 years | -99.31% |
52-Week Range
| 52-week High | $39.92 |
| 52-week Low | $1.64 |
| Avg Volume (90d) | 296K |
Technical Indicators
| SMA 50 | $3.62 |
| SMA 200 | $5.92 |
| Beta | 2.87 |
| 30-day Volatility (annualised) | 135.1% |
| Price vs SMA 50 | -53.1% |
| Price vs SMA 200 | -71.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $12.40 | |
| 2025-11 | $10.48 | -15.5% |
| 2025-12 | $6.00 | -42.7% |
| 2026-01 | $8.08 | +34.7% |
| 2026-02 | $5.96 | -26.2% |
| 2026-03 | $4.92 | -17.4% |
| 2026-04 | $7.03 | +42.9% |
| 2026-05 | $6.20 | -11.8% |
| 2026-06 | $5.55 | -10.5% |
| 2026-07 | $4.55 | -18.0% |
| 2026-08 | $1.68 | -63.1% |
| 2026-09 | $1.70 | +1.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $1.70 |
| Market Cap | $7M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.49 |
| EV / EBITDA | -0.44 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.30 |